Latest News
Estrogen–progestogen (combined) used as menopausal therapy, etoposide, etoposide in combination with cisplatin and bleomycin, methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) listed as known to cause cancer under Proposition 65.
| Program: Proposition 65
Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011
| Program: Proposition 65
Extension of public comment period regarding the removal of the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested.
| Program: Proposition 65
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) was listed effective 10/28/2011 as known to the State to cause cancer.
| Program: Proposition 65
Extension of comment period regarding the establishment of a specific regulatory level posing no significant risk for Imazalil.
| Program: Proposition 65
Notice of adoption to text of regulations Title 27, California Code of Regulations amendment to section 25805 Maximum Allowable Dose Level (MADL) for Avermectin B1
| Program: Proposition 65
Extension of public comment period on the changed notice of proposed rulemaking establishing a No Significant Risk Level: 4-Methylimidazole (4-MEI).
| Program: Proposition 65
Announcement of the October 12th and 13th2011 CIC meeting and hazard ID materials for fluoride and its salts, and tris(1,3-Dichloro-2-Propyl) phosphate. Both will be considered for listing at the October 2011 meeting.
| Program: Proposition 65
Comment period for the Changed Notice of Proposed Rulemaking Specific Regulatory Levels Posing No Significant Risk: 4-Methylimidazole (4-MEI).
| Program: Proposition 65
The proposed NSRL for 4-MEI has been changed from 16 to to 29 micrograms per day.
| Program: Proposition 65